Researchers at the Wyss Institute of Harvard University have used a mix of machine learning and classical screening techniques to identify small molecules that were effective against Neisseria gonorrhoeae in vagina-on-a-chip and mouse models of infection. Their findings were published in the June 17, 2026, issue of Science Translational Medicine.
On the eve of the June 17 Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting, which will discuss Moderna Inc.’s mRNA-1010, researchers at Washington University School of Medicine in St. Louis have reported that the vaccine conferred broader and more durable protection than a standard flu shot.
Technophage SA has obtained clinical trial clearances in Europe to initiate a phase I/IIa study of the bacteriophage cocktail TP-122 (component TP-122A) in Portugal and the Netherlands.
Innovative Molecules GmbH's new Epstein-Barr virus (EBV) antiviral program consists of several directly acting, highly potent, targeted polymerase inhibitors.
Brown University, Florida Atlantic University and Florida International University have jointly identified new compounds potentially useful for the treatment of malaria.
TRIM21, an enzyme involved in intracellular substrate degradation, can recognize viruses and bacteria that enter the cytosol when they are coated with antibodies. Just as it tags complex molecules for elimination, it can direct these infectious microorganisms to lysosomes through a mechanism its discoverers have termed antibody-directed xenophagy (ADX). Scientists at the Medical Research Council (MRC) Laboratory of Molecular Biology (LMB) in Cambridge, U.K., have identified the genes involved in this antibody-dependent degradation pathway, which acts as an antimicrobial process, and reported their findings in Molecular Cell on June 4, 2026.
Factor XIIa (FXIIa) has been explored as a therapeutic target for thrombosis and immune-mediated disorders due to its role at the interface of coagulation and inflammation. However, poor plasma stability and reversible target engagement have limited earlier approaches, underscoring the need for more durable next-generation inhibitors.
Researchers from Ospedale San Raffaele presented the preclinical characterization of SR-1891, a long-acting capsid assembly modulator (CAM) in models of chronic hepatitis B. In Hepa D38 cells, the compound exhibited EC50 and EC90 values of 0.2 and 0.8 nM, respectively, without any detectable cytotoxicity.
RSS
